Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT162b4 + BNT162b2 bivalent
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
**BNT162b4 + BNT162b2 bivalent** is a combination investigational mRNA COVID-19 vaccine comprising two distinct components: BNT162b4, which is an mRNA vaccine encoding conserved non-spike proteins from SARS-CoV-2 (specifically nucleocapsid, membrane, and ORF1ab proteins), and BNT162b2 bivalent, an mRNA vaccine encoding the spike protein of both the original (wild-type) SARS-CoV-2 and Omicron BA.4/BA.5 variants. BNT162b4 is designed to broaden T cell responses for increased protection and durability across SARS-CoV-2 variants. The bivalent BNT162b2 provides humoral immunity by presenting spike proteins from both the ancestral and Omicron lineages. The combination is intended to deliver enhanced and broad protection from severe COVID-19, by pairs of robust T cell and antibody responses, and is under clinical evaluation for this purpose. Both components are developed using BioNTech’s mRNA technology platform and administered intramuscularly[1][4].
- Other names
- Pfizer-BioNTech COVID-19 Vaccine BivalentOmicron BA.4/BA.5-adapted bivalent COVID-19 vaccine
02
Targets
SARS-CoV-2 spikeNSP3 (SARS-CoV-2 non-structural protein 3)M protein (SARS-CoV-2 membrane protein)N (Nucleocapsid protein)
Beyond the preview
Go deeper on BNT162b4 + BNT162b2 bivalent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT162b4 + BNT162b2 bivalent.